The American Society of Human Genetics (ASHG) is a nonprofit organization whose mission is to advance human genetics in science, health, and society through excellence in research, education, and advocacy. They hold a yearly essay contest for high schoolers, grades 9-12, promoting education and reflection upon genetic topics and awareness of DNA Day (Thursday, April…

To complement our 2018 Research Report, George and Leora will be sharing this year’s HD research highlights in our 2018 Research Year in Review Webinar on Wednesday, January 16th, 2019, from 12-1 pm Eastern time. Register to attend the webinar here.   New Year, New SAB Member HDSA’s Scientific Advisory Board (SAB) is composed of…

On Wednesday, December 19th, Roche/Genentech announced the US and Canadian locations for their upcoming study to test efficacy of the huntingtin-lowering therapy RG6042. This will be a 2-year study in people with early diagnosed HD. It will involve monthly lumbar punctures (spinal injections) to deliver RG6042 or a placebo, as well as clinical tests and scans…

This week, HDSA published the 2018 Research Report, a written re-cap of global HD research progress and how HDSA research dollars were put to use this year. We cover the work of HDSA-supported fellows, this year’s hot topics, conferences, clinical research news, and more, in a redesigned format. It’s a great summary of what happened…

The Ionis/Roche/Genentech Huntington’s program has received a lot of press in recent months. However, several additional companies have been working towards the same goal of developing therapies to target the genetic source of HD. One company is testing an antisense oligonucleotide (ASO) therapy, already in clinical trials, while others have novel drugs in the works…

We hope you had a Happy Thanksgiving, and a big thank you to our readers for your interest in research news and scientific activities at HDSA. Medicine moves forward through community engagement and research participation, along with the work of hundreds of health workers and scientists who have dedicated their lives to fighting HD. We’re…

On Saturday at the Huntington Study Group Meeting in Houston, Roche/Genentech announced the US and Canadian locations for their Natural History Study. This study does not involve drug treatments. It will monitor people with early manifest Huntington’s disease by testing their symptoms and measuring their mutant huntingtin levels over time. It will last for 16…

HDSA-supported researcher Dr. Amber Southwell is featured this week in an article about huntingtin-lowering. Her lab’s recent publication showed that an antisense oligonucleotide (ASO) designed to lower mutant huntingtin improved cognitive and behavioral problems in HD mice. Dr. Southwell was a 2015 HD Human Biology Fellow, and with HDSA’s support was able to transition to…

This week, we have opened up applications for HDSA research funding. Learn about how we support HD research and pass it on these opportunities to the scientists in your life! 2019 Berman/Topper Family HD Career Development Fellowship The Huntington’s Disease Society of America (HDSA) believes we must ensure that the pipeline of passionate and bright…

This week, we announced the winners of the 2018 HD Human Biology Fellowship. These young scientists were chosen for their well-designed projects that focus on understanding Huntington’s disease as it occurs in humans. Below are their names and the basic questions they will focus on in their HD research.  Rossana Foti, University of Copenhagen, Denmark:…